RXi Pharma (RXII) Stock: Here's Why It's Gaining


RXi Pharma is having an incredible time in the market as of late, and for a very good reason. It has been announced that the company received an Issue Notification from the United States Patent and Trademark Office. Today, we’ll talk about the details of the notification, how the market reacted to the news, and what we can expect to see from RXII moving forward. So, let’s get right to it…

RXII Receives An Issue Notification

As mentioned above RXi Pharma recently announced that it had received an Issue Notification from the United States Patent and Trademark Office, also known as USPTO. The notification revolved around a patent that covers specific methods for the treatment of compromised skin. The treatment now patented is known as self-delivering RNAi or sd-rxRNAs compounds targeting connective tissue growth factor (CTGF). The patent also includes RXI-109 to prevent, reduce or inhibit dermal scarring. According to the announcement, the US patent is #9,303,259 and will protect the company until the year 2029. In a statement, Dr. Geert Cauwenbergh, President and CEO at RXII had the following to say…

This issue notification from the USPTO further strengthens Rxi’s Intellectual Property position in the area of dermal scarring… From our ongoing Phase 2 clinical trial, we have already reported preliminary results indicating that the use of RXI-109 after scar revision surgery had a visible, beneficial effect on the suppression of hypertrophic scarring, at three months following revision surgery. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds for the treatment of dermal scarring, reinforcing the potential for future commercial and business development opportunities.”

How The Market Reacted To The News

As investors, one of the first things we learn is that when news comes out with regard to a publicly traded company, we can expect to see movement in the value of the stock associated with that company. If the news, is positive, the movement in the market will be as well. Adversely, negative news will cause declines in the value of the stock associated with the news. Considering the fact that RXII was recently issued a patent, we’re looking at overwhelmingly positive news. As a result, we’re seeing a positive reaction in the market. Yesterday, when the news was announced, RXII climbed in a big way. Today, we’re seeing a continuation on the gains. Currently (11:37), RXII is trading at $0.28 per share after a gain of $0.02 per share or 6.70% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I’m expecting to see incredibly positive movement out of RXII. The reality is that the company has made incredible advancements when it comes to improving dermal scarring, and as their innovation in the area continues, we can expect to see strong sales from their future products. Considering that the stock is trading at an incredibly low value at the moment, even a light improvement in the value of the stock can lead to incredible gains. All in all, I’m overwhelmingly impressed with what I’m seeing and expect to see long term gains from the company.

What Do You Think?

Where do you think RXII is headed moving forward? Let us know your opinion in the comments below!